Award Recognizes Chimerix As a Top Company in North America That Drives the
Technology Industry's Future
SAN DIEGO, May 12 /PRNewswire/ -- Chimerix Inc., an emerging biotechnology
company developing orally available antiviral therapeutics, today announced
that it has been named one of the Red Herring 100 Private Companies of North
America. Chimerix was chosen as one of the top emerging biotechnology
companies for the company's vision, management expertise, and overall
potential to change the way disease is treated.
"Five years after the dot-com bubble burst, innovation and
entrepreneurship are thriving. The companies on this list are proof," said
Red Herring editor-in-chief Joel Dreyfuss.
"The broad application of our proprietary technology allows the company to
quickly develop critical drug candidates for a variety of viral diseases, the
most advanced of which is CMX001, our lead antiviral agent for treatment of
smallpox infection," said George Painter, Ph.D., president and CEO of
Chimerix, Inc. "Chimerix is honored to be chosen from among so many
outstanding private companies in the technology industry, and to be recognized
for the company's experienced team of professionals and corporate vision."
Red Herring's lists of private companies are an important part of the
magazine's tradition of identifying new and innovative technology companies
and entrepreneurs. Companies like Google and eBay were spotted in their early
days by Red Herring editors as those that would change the way we live and
work.
Red Herring's editorial staff rigorously evaluated more than 900 private
companies through a careful analysis of financial data and subjective
criteria, including quality of management, execution of strategy, and
dedication to research and development. Red Herring 100 companies will be
presenting their business model and strategy at the Red Herring Spring
conference. Red Herring Spring will take place May 17-19 at the Monterey
Plaza Hotel in Monterey, California.
About Chimerix
Chimerix Inc. is a privately held biotechnology company creating and
developing orally available medicines from bioactive molecules. Application
of Chimerix's proprietary technology enhances oral availability, stabilizes
drug in plasma, and facilitates the delivery of drugs into targeted tissues.
Known drugs can be modified to improve dosing parameters, broaden therapeutic
applications and decrease the risk of adverse reactions. Chimerix is applying
its technology towards discovery and development of oral drugs for the
treatment of smallpox, cytomegalovirus infection, drug-resistant HIV infection
and viral hepatitis. Chimerix was founded in 2002 and is headquartered in
San Diego, CA, with offices in Research Triangle Park, NC.
About Red Herring Spring
Red Herring Spring is an invitation-only event for CEOs, select senior
executives, and Venture Capitalists. Themed 'The Dynamics of Disruptions',
Red Herring Spring 2005 will bring together executives from mostly private
companies. These executives will be joined by senior executives from public
companies and Venture Capitalists. Please contact Sean Raman at 650.428.2900
or email sraman@redherring.com if you would like to request an invitation to
Red Herring Spring.
About Red Herring
Red Herring is the weekly magazine technology entrepreneurs, investors and
industry observers read to stay ahead of the curve and to be better informed
about the global marketplace. Red Herring covers technology, innovation,
financial strategies, important personalities and trends that are transforming
the world of business with unique insight, opinion and forward-looking
analysis. Readers turn to Red Herring for knowledge to make strategic
decisions, build companies and create a competitive advantage for their
businesses. Red Herring articles, blogs, research and event information can
be found online at http://www.redherring.com.
SOURCE Chimerix, Inc.
 back to top
Related links:
http://www.redherring.com
CONTACT:
Amy Beltran, Ph.D. of Atkins + Associates,
+1-858-527-3489, abeltran@irpr.com, for Chimerix, Inc.
|
